-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $225

Benzinga·05/15/2026 14:51:34
Listen to the news
Piper Sandler analyst David Amsellem reiterates Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $214 to $225.